Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context

Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gullapalli, Sneha, Remon, Jordi, Hendriks, Lizza E L, Lopes, Gilberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369644/
https://www.ncbi.nlm.nih.gov/pubmed/32764980
http://dx.doi.org/10.2147/OTT.S259308

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369644/
https://www.ncbi.nlm.nih.gov/pubmed/32764980
http://dx.doi.org/10.2147/OTT.S259308

Ejemplares similares